Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03786926 · ClinicalTrials.gov registry record · Phase 1
Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas
A Phase 1 study, sponsored by Hutchmed.
- Terminated
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
NCT03786926: Clinical Trial Phase 1 study, sponsored by Hutchmed.
NCT03786926 is a Phase 1 study that was terminated before completion, run by Hutchmed. The registered enrollment target is 53 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (12% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03786926, a Phase 1 study, was terminated before completion, sponsored by Hutchmed.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
An open-label, dose escalation and expansion clinical trial to evaluate the safety, tolerability and PK of HMPL-689 in patients with relapsed or refractory lymphomas
Primary Outcome
A DLT was defined as the occurrence of any of the following treatment-emergent adverse events (TEAEs) during the DLT assessment window, unless equivocally due to underlying malignancy or an extraneous cause. AEs were graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0: non-hematologic toxicity: all non-hematologic TEAEs of grade 3 or greater with the exception of grade 3 nausea or vomiting that could be controlled by supportive therapy;
Interventions
- DRUG HMPL-689
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2019-08-26 |
| Est. Completion | 2024-06-26 |
| Phase | Phase 1 |
Why NCT03786926 stopped before completion
NCT03786926 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (12% lower).
The record links to 0 conditions, and to 1 intervention - of which HMPL-689 is the first listed.
NCT03786926 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03786926 about?
NCT03786926 is a clinical study titled "Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas". An open-label, dose escalation and expansion clinical trial to evaluate the safety, tolerability and PK of HMPL-689 in patients with relapsed or refractory lymphomas
What is the current status of trial NCT03786926?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2019-08-26. Estimated completion is 2024-06-26.
What interventions are being tested in trial NCT03786926?
The interventions under investigation include: HMPL-689 (DRUG).
Who is sponsoring clinical trial NCT03786926?
This trial is sponsored by Hutchmed, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03786926's enrollment target sits among peer trials
53 948th of 2000 higher than 1,045 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI